Project Newsletter | Autumn 2024
The final dash is on! This newsletter offers a brief overlook on latest activities, including Coordinator’s greetings, list of the latest blog series and events.
Dear HEDIMED partners and followers,
it is time for a recall in the form of a short letter. It is exciting to see all the progress that has made by HEDIMED during the past months – we are currently in a very productive phase. Looking at our publications list is astonishing – we truly have made it this far!
The first half of 2024 has run by quickly, and alongside the hectic scientific work, HEDIMED’s administrative effort has focused on the preparation of the amendment for the project plan. We are still waiting for the European Commission to give their official statement on the desired project extension and will shortly inform you about the decision. Moreover, our hands have been full of several European Human Exposome Network (EHEN) coordination activities, the responsibility of which is shared with two other EU-funded exposome research projects, REMEDIA and EPHOR. This collaboration has also been very productive, and we are glad to be involved in organizing the EHEN scientific and stakeholder meetings in Brussels in November! Also, being part of the lead in the last active months of EHEN, the preparation of the EHEN policy brief and planning of the stakeholder interaction have been an invaluable learning experience, and more are sure to follow!
Looking into the future, there is anticipation for several new publications, implementation of the toolbox, a few more blog posts, one more on-site Consortium meeting, and finally, building of stakeholder interaction by the end of the project. I am looking forward to the most exciting phase of this big project and wish everyone an enjoyable shift from summer to fall – and from vacations to offices!
Stay tuned and read more about HEDIMED’s highlights in this newsletter and X !
Best,
Heikki Hyöty
A quick throwback into EASD2024, held in Madrid in 9th-13th September: This year, EASD brought together a large and engaged audience of more than 12,000 people, with particular interest in Type 1 Diabetes. The event, designed to bridge the gap between scientific discoveries and public health, featured key presentations and discussions about the disease. HEDIMED
HEDIMED was featured in the European Commission’s Horizon Research & Innovation Magazine. Read the article “The hunt for clues to immune-system disorders” on how HEDIMED is taking approaches to understanding a growing group of illnesses in a bid for more effective treatments. https://projects.research-and-innovation.ec.europa.eu/en/horizon-magazine/hunt-clues-immune-system-disorders
We proudly share a comprehensive list of blog publications on our website. You may have a look at the latest blog posts about novel technologies used in HEDIMED research, such as Array-in-well, mesoscale, allergy testing device and fecal volatilomics. In addition, we have written blog posts from the dietary perspective of exposome, see the list below.
Celiac disease, a condition where the immune system reacts abnormally to gluten, used to be considered rare. Today, it’s being diagnosed more than ever – especially in children. But this increase isn’t just due to better testing. Evidence suggests the disease itself is becoming more common, at least in certain countries (King et al. 2020).
Advancing the use of health data in a secure and collaborative manner is critical for driving innovation in exposome research. The European Health Data Space (EHDS) is an EU initiative designed to facilitate the secure sharing and utilization of health data for healthcare, research, and policymaking across member states. It plays a pivotal role in
Like other immune-mediated diseases, allergic diseases have been increasing in the Western world at the same time as economic and societal development, urbanization, and Western lifestyle in general. Allergic diseases include allergic asthma, allergic rhinitis, food allergy, atopic eczema, and as a severe case anaphylaxis. The European Academy of Allergy and Clinical Immunology (EAACI) has
Novel Technologies used in HEDIMED Volatile organic compounds (VOCs) are substances that readily evaporate in our ordinary living environment. This means that they have a high vapour pressure at room temperature and low boiling point, which facilitates their volatility and makes them responsible for odours and smells. VOCs are a diverse group of compounds derived
Novel Technologies used in HEDIMED One of the main aims of the HEDIMED project is to investigate what is behind the epidemic of immune-related diseases, and there is a wide range of different exposures under research. Among other things, several infections have been associated with autoimmune diseases or the mechanisms behind them. For example, some
Novel technologies used in Hedimed Amidst the rising tide of allergies and sensitivities, such as reactions to specific foods and pollen, CSEM stands as a beacon of innovation through the HEDIMED project. Guided by the expertise of Loïc Burr and Stefano Cattaneo at CSEM’s Landquart research facilities in Switzerland, this transformative technology is poised to
EHEN network meeting, autumn 2024
The European Human Exposome Network has its final meeting between in Brussels, 26th-28th November 2024. There will be two scientific days and one day for EHEN Stakeholder Event.
Registeration is open until 15th October. Stay tuned for more EHEN related news!
HEDIMED Consortium meeting, spring 2025
The final HEDIMED Consortium meeting has been planned for 8th-11th April 2025 in Siena, Italy. This meeting will be internal for the most part, details will follow.
The European Human Exposome Network (EHEN) is the world’s largest network of projects studying the impact of environmental exposure on human health. It brings together 9 EU research projetcs that address issues such as exposures to air quality, noise, chemicals, urbanisation etc. and health impacts.
Read more about EHEN and see their latest news.
